MaxCyte appoints Patrick Balthrop as non-executive director; grants 100,000 stock options

MAXCYTE, INC.

Patrick Balthrop appointed as Class II director and member of Nominating and Corporate Governance Committee effective Nov 30, 2022.
Granted 100,000 nonqualified stock options at $5.99/share, vesting over three years with 1/3 after 12 months.
Balthrop has 35+ years in life sciences; former CEO of Luminex, President of Fisher Healthcare, Abbott Laboratories veteran.
No related party transactions or family relationships with existing directors or officers.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patrick J. Balthrop, Sr.

Class II director

MXCT · MAXCYTE, INC.

Effective: 2022-11-30
Filed: December 1, 2022, 6:59 PM ET

On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “ Nominating Committee ”), the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Patrick J. Balthrop, Sr. to serve as a Class II director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick J. Balthrop, Sr. was appointed as Class II director at MAXCYTE, INC..

Action: appointed
Role: Class II director

Exact text from the filing

On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “ Nominating Committee ”), the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Patrick J. Balthrop, Sr. to serve as a Class II director.

View on SEC.gov

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-123467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.